InvestSMART

Cambium Bio Limited (ASX:CMB)

ALERT: Price-sensitive ASX Announcement for CMB
Current share price for CMB : $0.435 0.05 (12.99%)+
Announcement
Release
23 Apr 2026 1:01PM
Price at Release
$0.385
Full Release
download
Summary
Cambium Bio Limited announced that the FDA has confirmed a single pivotal trial pathway for their Elate Ocular® drug, aimed at treating moderate-to-severe dry eye disease. This decision allows Cambium Bio to conduct a single, well-controlled Phase 3 study, significantly reducing development costs and accelerating the timeline for regulatory approval. The FDA's approval of this pathway enhances the probability of success by focusing on one comprehensive study rather than multiple trials. The study design has been confirmed to include 400 subjects, focusing on both sign and symptom endpoints over a 9-week treatment period. Elate Ocular® also benefits from a Fast Track Designation, allowing for a rolling submission of the Biologics License Application (BLA). Cambium Bio is now focused on initiating the pivotal trial as soon as feasible, with patient enrolment expected in 2026.
Key Points
  • FDA confirms single-trial pathway for Elate Ocular®.
  • Significant reduction in development cost and accelerated timeline.
  • Increased probability of success with a single well-powered study.
  • Phase 3 study design confirmed with 400 evaluable subjects.
  • Fast Track Designation allows rolling BLA submission.
  • Focus on initiating pivotal Phase 3 study with enrolment in 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.